公开(公告)号：US20080175873A1

公开(公告)日：2008-07-24

申请号：US11947883

申请日：2007-11-30

Applicant: Fang Zhou ,  Paul Maes ,  Steven Frisbee

Inventor： Fang Zhou ,  Paul Maes ,  Steven Frisbee

IPC: A61K9/00 ,  A61K31/137 ,  A61P25/24

CPC classification number: A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/284 ,  A61K9/2866

Abstract: The present invention relates to a modified release composition of at least one form of venlafaxine, which is an enhanced absorption delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially surrounds the core which provides a delayed controlled release of the at least one form of venlafaxine.

Abstract translation: 本发明涉及至少一种形式的文拉法辛的改进释放组合物，其是增强的吸收延迟控释组合物。 组合物包含包含至少一种形式的文拉法辛，小于10％的胶凝剂和药学上可接受的赋形剂的核心。 所述组合物还包含基本上围绕所述芯的改性释放涂层，其提供所述至少一种形式的文拉法辛的延迟控制释放。

公开(公告)号：US08110219B2

公开(公告)日：2012-02-07

申请号：US12328828

申请日：2008-12-05

Applicant: Steven Frisbee

Inventor： Steven Frisbee

IPC: A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  A61K9/38

Abstract: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.

公开(公告)号：US08323692B2

公开(公告)日：2012-12-04

申请号：US12328828

申请日：2008-12-05

Applicant: Steven Frisbee

Inventor： Steven Frisbee

IPC: A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  A61K9/38

CPC classification number: A61K9/2893 ,  A61K9/2009 ,  A61K9/2027 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/2866 ,  A61K31/135

Abstract: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.

Abstract translation: 本发明提供用于涂覆药物口服剂型的稳定的控释单片涂料组合物，其包含熔点大于55℃的聚二醇和缺乏官能团的中性酯共聚物的水分散体。

公开(公告)号：US20090258067A1

公开(公告)日：2009-10-15

申请号：US12425819

申请日：2009-04-17

Applicant: Fang ZHOU ,  Paul Maes ,  Steven Frisbee

Inventor： Fang ZHOU ,  Paul Maes ,  Steven Frisbee

IPC: A61K9/24 ,  A61K31/137

CPC classification number: A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/284 ,  A61K9/2866

Abstract: The present invention relates to a modified release composition of at least one form of venlafaxine, which is an enhanced absorption delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially surrounds the core which provides a delayed controlled release of the at least one form of venlafaxine.

Abstract translation: 本发明涉及至少一种形式的文拉法辛的改进释放组合物，其是增强的吸收延迟控释组合物。 组合物包含包含至少一种形式的文拉法辛，小于10％的胶凝剂和药学上可接受的赋形剂的核心。 所述组合物还包含基本上围绕所述芯的改性释放涂层，其提供所述至少一种形式的文拉法辛的延迟控制释放。